FIELD: pharmaceutics.
SUBSTANCE: present invention relates to an injection composition containing 1-(5-(2,4-difluorophenyl)-1-((3-fluorophenyl)sulfonyl)-4-methoxy-1H-pyrrol-3-yl)-N-methyl methanamine.
EFFECT: improved stability and solubility of the composition for injections.
9 cl, 10 tbl, 5 ex
| Title | Year | Author | Number |
|---|---|---|---|
| COMPOSITIONS CONTAINING ACETAMINOPHENE AND CYCLODEXTRIN SULFAOKYL ETHER | 2017 |
|
RU2772384C2 |
| AQUEOUS COMPOSITION CONTAINING DANTROLENE | 2016 |
|
RU2729043C2 |
| COMPOSITION AND MICROSPHERE WITH CONTROLLED EXENDIN RELEASE AND METHOD OF OBTAINING MICROSPHERE | 2008 |
|
RU2463040C2 |
| NOVEL ACID SECRETION INHIBITOR AND ITS USE | 2021 |
|
RU2815697C1 |
| PHARMACEUTICAL COMPOSITION INCLUDING 5-{4-(AMINOSULFONYL)PHENYL}-2,2-DIMETHYL-4-(3-FLUOROPHENYL)-3(2H)-FURANONE AND CAPSULE FORMULATION INCLUDING PHARMACEUTICAL COMPOSITION | 2015 |
|
RU2681932C2 |
| STABLE COMPOSITIONS OF NEUROACTIVE PEPTIDES | 2015 |
|
RU2716164C2 |
| GLYCOPEPTIDE ANTIBIOTIC SALT AND PHARMACEUTICAL COMPOSITIONS BASED THEREON | 2023 |
|
RU2827992C1 |
| 2,3-DIHYDRO-ISOINDOL-1-ONE DERIVATIVES AND METHODS FOR USE THEREOF AS BRUTON'S TYROSINE KINASE INHIBITORS | 2013 |
|
RU2671847C2 |
| LIQUID COMPOSITIONS (S)-N-(5-((R)-2-(2,5-DIFLUOROPHENYL)PYRROLIDINE-1-YL)PYRAZOLO[1,5-A]PYRIMIDINE-3-YL)-3-HYDROXYPYRROLIDINE-1-ARBOXAMIDE | 2017 |
|
RU2751767C2 |
| ANTICANCER COMPOSITION | 2019 |
|
RU2789245C2 |
